International Clinical Trial: A single-dose, randomized, open-label, two-period, two-sequence, double-crossover bioequivalence study of Vericiguat Tablets in healthy trial participants under fed conditions

Geneva, Oct. 27 -- International Clinical Trials Registry received information related to the study (ChiCTR2600134550) titled 'A single-dose, randomized, open-label, two-period, two-sequence, double-crossover bioequivalence study of Vericiguat Tablets in healthy trial participants under fed conditions' on Oct. 16.

Study Type: Interventional study

Study Design: Cross-over

Primary Sponsor: Deyang People's Hospital

Condition: Malignant chronic heart failure and reduced left ventricular ejection fraction

Intervention: Group B (R-T sequence):In the first period, a single dose of 1 tablet (5 mg) of the reference formulation of vericiguat tablets was administered in the second period, a single dose of 1 tablet (5 mg) of the test formulat...